Notably, sorafenib reversed the pro-phosphorylation effect of PRI-724 on AKT, with their combination synergistically inhibiting AKT phosphorylation at Ser473 (Fig. 5H, I), which is associated with the promotion of tumor cell viability [41–43]. This evidence concerns the gene AKT1 and neoplasm.